Integrated Strategies For Drug Discovery Using Mass Spectrometry

* Shares historical background information on various techniques to aid in the understanding of how and why new methods are now being employed to analyze samples

MIKE S. LEE, PHD is President of Milestone Development Services. He is actively involved with consulting, workshops, and symposia to connect industry needs with innovative technologies and solutions. His research interests include the applications of mass spectrometry for the analysis of proteins, natural products, drug metabolites, impurities, and degradants. Recent work has involved the development of automated orthogonal control systems for electrospray ionization. Formerly, Dr. Lee was director of analytical research and development at Bristol-Myers Squibb (BMS) Pharmaceutical Research Institute where he led interdisciplinary teams that contributed to the Food and Drug Administration's approval of Buspar® and Serzone, and the accelerated development and approval of TAXOL. Dr. Lee is a member of the American Society of Mass Spectrometry, American Association of Pharmaceutical Scientists, and the American Chemical Society. In addition, he has authored over forty scientific papers and issued patents.